| Literature DB >> 30108990 |
Yves Depetter1,2,3, Silke Geurs1, Flore Vanden Bussche1, Rob De Vreese1, Jorick Franceus4, Tom Desmet4, Olivier De Wever2,3, Matthias D'hooghe1.
Abstract
Recent studies point towards the possible disadvantages of using hydroxamic acid-based zinc-binding groups in HDAC inhibitors due to e.g. mutagenicity issues. In this work, we elaborated on our previously developed Tubathian series, a class of highly selective thiaheterocyclic HDAC6 inhibitors, by replacing the benzohydroxamic acid function by an alternative zinc chelator, i.e., an aromatic trifluoromethyl ketone. Unfortunately, these compounds showed a reduced potency to inhibit HDAC6 as compared to their hydroxamic acid counterparts. In agreement, the most active trifluoromethyl ketone was unable to influence the growth of SK-OV-3 ovarian cancer cells nor to alter the acetylation status of tubulin and histone H3. These data suggest that replacement of the zinc-binding hydroxamic acid function with a trifluoromethyl ketone zinc-binding moiety within reported benzohydroxamic HDAC6 inhibitors should not be considered as a standard strategy in HDAC inhibitor development.Entities:
Year: 2018 PMID: 30108990 PMCID: PMC6072519 DOI: 10.1039/c8md00107c
Source DB: PubMed Journal: Medchemcomm ISSN: 2040-2503 Impact factor: 3.597